Implementation of an enoxaparin protocol for venous thromboembolism prophylaxis in obese surgical intensive care unit patients;Implantación de un protocolo de enoxaparina para profilaxis de tromboembolismo venoso en pacientes obesos de una unidad de cuidado intensivo de cirugía

Annals of Pharmacotherapy

Volumn 45, Issue 11, 2011, Pages 1356-1362

  Ludwig, Kyle P ^a   Simons, Heidi J ^a   Mone, Mary ^a   Barton, Richard G ^a   Kimball, Edward J ^a  

^a UNIVERSITY OF UTAH HOSPITAL   (United States)

Author keywords

Anti Xa levels; Critically ill; Enoxaparin; Obesity; Venous thromboembolism

Indexed keywords

BLOOD CLOTTING FACTOR 10A; ENOXAPARIN;

ADULT; AGED; ARTICLE; BLEEDING; BODY MASS; BODY WEIGHT; CLINICAL ARTICLE; DEEP VEIN THROMBOSIS; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; FEMALE; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; INTENSIVE CARE; MALE; MORBID OBESITY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; THROMBOSIS PREVENTION; TRACHEAL HEMORRHAGE; VENOUS THROMBOEMBOLISM;

ADOLESCENT; ADULT; AGED; ANTICOAGULANTS; BODY MASS INDEX; DRUG ADMINISTRATION SCHEDULE; ENOXAPARIN; FEMALE; HEMORRHAGE; HUMANS; INTENSIVE CARE UNITS; MALE; MIDDLE AGED; OBESITY, MORBID; RETROSPECTIVE STUDIES; VENOUS THROMBOEMBOLISM; YOUNG ADULT;

EID: 80155191276     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1Q313     Document Type: Article

References (24)

1. Geerts WH, Bergqvist D, Pineo GF, et al. Prevention of venous thromboembolism: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition). Chest 2008;133:381S-453S. DOI 10.1378/chest.08-0656
2. Edmonds MJ, Crichton TJ, Runciman WB, Pradhan M. Evidence-based risk factors for postoperative deep vein thrombosis. ANZ J Surg 2004; 74:1082-97. DOI 10.1111/j.1445-1433.2004.03258.x
3. Anderson FA Jr, Spencer FA. Risk factors for venous thromboembolism. Circulation 2003;107:I9-16.
4. Caterson ID. Medical management of obesity and its complications. Ann Acad Med Singapore 2009;38:22-7.
5. Diehl AM. Hepatic complications of obesity. Gastroenterol Clin North Am 2010;39:57-68. DOI 10.1016/j.gtc.2009.12.001
6. Doyle SL, Lysaght J, Reynolds JV. Obesity and post-operative complications in patients undergoing non-bariatric surgery. Obes Rev 2010;11:875-86. DOI 10.1111/j.1467-789x.2009.00700.x
7. Leinum CJ, Dopp JM, Morgan BJ. Sleep-disordered breathing and obesity: pathophysiology, complications, and treatment. Nutr Clin Pract 2009;24:675-87. DOI 10.1177/0884533609351532
8. James WP. WHO recognition of the global obesity epidemic. Int J Obes (Lond) 2008;32(suppl 7):S120-6. DOI 10.1038/ijo.2008.247
9. Poulose BK, Griffin MR, Zhu Y, et al. National analysis of adverse patient safety for events in bariatric surgery. Am Surg 2005;71:406-13.
10. McCarty TM, Arnold DT, Lamont JP, Fisher TL, Kuhn JA. Optimizing outcomes in bariatric surgery: outpatient laparoscopic gastric bypass. Ann Surg 2005;242:494-8; discussion 498-501.
11. Scholten DJ, Hoedema RM, Scholten SE. A comparison of two different prophylactic dose regimens of low molecular weight heparin in bariatric surgery. Obes Surg 2002;12:19-24. DOI 10.1381/096089203231144522
12. Hamad GG, Choban PS. Enoxaparin for thromboprophylaxis in morbidly obese patients undergoing bariatric surgery: findings of the prophylaxis against VTE outcomes in bariatric surgery patients receiving enoxaparin (PROBE) study. Obes Surg 2005;15:1368-74DOI 10.1381/096089205774859245
13. Borkgren-Okonek MJ, Hart RW, Pantano JE, et al. Enoxaparin thromboprophylaxis in gastric bypass patients: extended duration, dose stratification, and antifactor Xa activity. Surg Obes Relat Dis 2008;4:625-31. DOI 10.1016/j.soard.2007.11.010
14. Haas CE, Nelsen JL, Raghavendran K, et al. Pharmacokinetics and pharmacodynamics of enoxaparin in multiple trauma patients. J Trauma 2005;59:1336-43; discussion 1343-4. DOI 10.1097/01.ta.0000197354.69796.bd
15. Rutherford EJ, Schooler WG, Sredzienski E, Abrams JE, Skeete DA. Optimal dose of enoxaparin in critically ill trauma and surgical patients. J Trauma 2005;58:1167-70. DOI 10.1097/01.ta.0000172292.68687.44
16. Duplaga BA, Rivers CW, Nutescu E Dosing and monitoring of lowmolecular-weight heparins in special populations. Pharmacotherapy 2001;21:218-34. DOI 10.1592/phco.21.2.218.34112
17. Nutescu EA, Spinler SA, Wittkowsky A, Dager WE. Low-molecularweight heparins in renal impairment and obesity: available evidence and clinical practice recommendations across medical and surgical settings. Ann Pharmacother 2009;43:1064-83. DOI 10.1345/aph/1L194
18. Frezza EE, Chiriva-Internati M. Venous thromboembolism in morbid obesity and trauma. A review of literature. Minerva Chir 2005;60:391-9.
19. Rowan BO, Kuhl DA, Lee MD, Tichansky DS, Madan AK. Anti-Xa levels in bariatric surgery patients receiving prophylactic enoxaparin. Obes Surg 2008;18:162-6. DOI 10.1007/s11695-007-93814
20. Hirsh J, Bauer KA, Donati MB, Gould M, Samama MM, Weitz JI. Parenteral anticoagulants: American College of Chest Physicians evidencebased clinical practice guidelines (8th edition). Chest 2008;133:141S-59S. DOI 10.1378/chest.08-0689
21. Simone EP, Madan AK, Tichansky DS, Kuhl DA, Lee MD. Comparison of two low-molecular-weight heparin dosing regimens for patients undergoing laparoscopic bariatric surgery. Surg Endosc 2008;22:2392-5. DOI 10.1007/s00464-008-9997-6
22. Rondina MT, Wheeler M, Rodgers GM, Draper L, Pendleton RC. Weight-based dosing of enoxaparin for VTE prophylaxis in morbidly obese, medically-ill patients. Thromb Res 2010;125:220-3. DOI 10.1016/j.thromres.2009.02.003
23. Cheymol G. Effects of obesity on pharmacokinetics implications for drug therapy. Clin Pharmacokinet 2000;39:215-31. DOI 10.2165/00003088-200039030-00004
24. Lin H, Faraklas I, Cochran A, Saffle J. Enoxaparin and antifactor Xa levels in acute burn patients. J Burn Care Res 2011;32:1-5.